Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5-Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with In Vivo Efficacy against MRSA
[EN] BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS BICYCLIQUES PONTÉS POUR LE TRAITEMENT DES INFECTIONS BACTÉRIENNES
申请人:KYORIN SEIYAKU KK
公开号:WO2013003383A1
公开(公告)日:2013-01-03
Novel bridged bicyclic compounds are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antibacterial agents. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating bacterial infections and associated diseases and conditions.
5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, A Process for Their Production and Their Use as Anti-inflammatory Agents
申请人:Berger Markus
公开号:US20090137564A1
公开(公告)日:2009-05-28
The present invention relates to compounds of formula I,
processes for their production and their use as anti-inflammatory agents.
本发明涉及公式I的化合物,其生产过程以及作为抗炎药物的用途。
[EN] PROCESS FOR THE PREPARATION OF 5-AMINO-QUINOLIN-2(1H)-ONES AND THEIR TAUTOMER FORMS 5-AMINO-QUINOLIN-2-OLS<br/>[FR] PROCÉDÉ DE PRÉPARATION DE 5-AMINO-QUINOLIN-2(1H)-ONES ET DE LEURS FORMES TAUTOMÈRES, LES 5-AMINO-QUINOLIN-2-OLS
申请人:BAYER PHARMA AG
公开号:WO2017025371A1
公开(公告)日:2017-02-16
The present invention relates to a novel process for the preparation of 5-Amino-quinolin-2(1H)- ones and its tautomer's 5-amino-quinolin-2-ols. The present invention further comprises various novel compounds which are obtained during the preparation of 5-Amino-quinolin-2(1H)-ones and its tautomer's 5-amino-quinolin-2-ols.
In recognition of the unmet need to develop novel therapeutic agents, the present invention discloses a novel class of heterocycles as dual inhibitors of BRD4 and class I PI3Ks. The compounds claimed herein could be used alone or in combination therapies for the effective treatment of a wide range of age-related diseases, including cancer. The present invention also provides methods for preparing compounds of the invention thereto.